LAP7 Rec'd PCT/PTO 13 JUN 2006P CT

JUN 1 3 2006 8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on June 8, 2006

(lik-She

Chih-Sheng Lin

Dated: June 8, 2006

Patent

Docket No. : J660-065 US

Firm : Notaro & Michalos P.C.

Fax No. : (845) 359-7798

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Thomas Helleday, et al.

Application No.

10/565,308

PCT No.

PCT/GB04/03183

PCT Date

July 25, 2004

For

Therapeutic Compounds

21 Pages and One (1) Floppy Disk Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

COMMUNICATION IN RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir/Madam:

This communication is responsive to the Notification to Comply with Requirements for Patent Application Containing Nucleotide and/or Amino Acid Sequence Disclosures dated May 11, 2006 (hereinafter referred to as the "Notification"). A copy of the Notification is attached herein as **Exhibit A**.

REMARKS:

In response to the Notification, Applicants hereby submit on a floppy disk

accompanying this Communication a computer readable form of the sequence listing part

of this application (hereinafter referred to as the "sequence listing"). A written copy of

sequence listing recorded in computer readable form is also attached herein as Exhibit

B. '

Applicants further submit that the information recorded in computer readable form

is identical to the written sequence listing, and that no new matter has been added to the

sequence listing.

It is believed that all requirements set forth in the Notification have been satisfied.

Accordingly, favorable action is respectfully requested.

If any issues remain which may be resolved, the Examiner is respectfully invited

to contact the undersigned at the number below.

Favorable action is respectfully requested.

Respectfully submitted,

Chih-Sheng Lin

Reg. No. 56,402

Attorney for Applicants

ph. (845) 359-7700

Dated: June 8, 2006

NOTARO & MICHALOS P.C.

100 Dutch Hill Road, Suite 110 Orangeburg, New York 10962-2100

Customer No. 21706

F:\TEXT\PATAMD\J660-065 US SEQ LISTING.wpd



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS
PO MORE TO MAIN AUGUST 1999
Alexandra, Virginia 22313-1450

110 100100100000000000000			
U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATT	Y. DOCKET NO.
10/565,308	Thomas Helleday	J660-065 US	
	1 F 000C	INTERNATIONAL APPLICATION NO.	
021706	MAY 1 5 2006	PCT/GB04/03183	
NOTARO AND MICHALOS		I.A. FILING DATE	PRIORITY DATE
	30 & MEDITALOS 1951	07/23/2004	07/25/2003
ORANGEBURG, NY 10962-2100	CONFIRMATION NO. 9807		
*	PIRES July 11, 2006	371 FORMALITIES LETTER	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

		
U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/565,308	PCT/GB04/03183	J660-065 US

FORM PCT/DO/EO/922 (371 Formalities Notice)

.)